Greetings and welcome to Longeveron's call today to discuss the results of the company's Phase 2b Aging Frailty trial and Second Quarter 2021 Financial Results. All participants are currently in a listen-only mode. Following the formal presentation, we will open the call up for question-and-answer session.

[Operator Instructions] I'd now like to turn the call over to Brendan Payne from Stern IR. Brendan, you may proceed..

Thank you, operator. Good morning everyone and welcome to Longeveron's call today to discuss the results of its U.S. Phase 2b trial of Lomecel-B and the Aging Frailty, and second quarter 2021 business update and financial results.

Earlier this morning, Longeveron issued a press release summarizing its second quarter 2021 financial results with a corporate update that we will discuss on today's call.

Concurrent with the aforementioned release, Longeveron also issued a press release this morning, announcing the top-line results from its recently completed Phase 2b clinical trial with Lomecel-B and subjects with Aging Frailty. You can access both press releases by going to the new section of Longeveron's website longeveron.com.

I'm joined on the call today with the following members of Longeveron's management team. Mr. Geoff Green, Chief Executive Officer; Mr. Joshua Hare, Co-Founder, Chief Science Officer and Chairman; and James Clavijo, the Chief Financial Officer.

We're going to begin the update with a detailed overview of the top-line data from the Phase 2b trial, which was announced this morning. This clinical trial results discussion will be provided by Dr. Hare. After that Mr.

Green will give a brief general update and summary of recent events, and we will conclude with a recap of our financial results from the second quarter of 2021, followed by Q&A period.

As a reminder, during this call, we'll be making forward-looking statements which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements.

Any such statement should be considered in conjunction with cautionary statements in our press releases and risk factors discussion in our filings with the SEC, including our last Annual Report, or Form 10-K, and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

Now, I'd like to turn the call over to Dr. Joshua Hare, Co-Founder, Chief Science Officer and Chairman of Longeveron. Dr.

Hare?.

25 million cells, there were 37 recipients, 50 million cells n equals 31, 100 million cells n equals 34, 200 million cells n equals 16 and placebo n equals 30.

The main inclusion criteria for entry into the trial was 70 to 85 years of age, a screening six-minute walk test of between 200 and 400 meters, a Canadian Health and Safety Assessments, abbreviated as CHSA, clinical frailty score of five or six, five is mildly frail, six is moderately frail and a minimum serum TNF-α of greater than 2.5 micrograms per ML.

TNF-α is a marker of inflammation in the blood. We selected as our primary endpoint to six minute walk test distance. Safety and efficacy evaluations were conducted at 90, 180 and 270 days after infusion. The six-minute walk test is a validated field study.

It's widely used to assess functional exercise capacity, treatment effectiveness and prognosis because it is accurate, reproducible, easy to administer and well tolerated.

It has been used as the basis for FDA approval for many drugs and indications, such as pulmonary arterial hypertension, COPD, Hunter syndrome and Morquio A syndrome, which is a lysosomal storage disorder.

The six minute walk test is particularly applicable to Aging Frailty because the test is an integrated global assessment of cardiac, respiratory, circulatory and muscular capacity.

Age-related loss of skeletal muscle, sarcopenia, leading to diminished strength, lack of endurance and low tolerance of physical exertion, a common core clinical presentations of Aging Frailty. The six minute walk test, therefore, can be used as a meaningful reflection of a patient's ability to perform basic activities of daily living.

Statistics indicate that 40% of community dwelling adults over 75 years of age has difficulty walking even a quarter mile, which is 400 meters, which is the U.S. Census Bureau Standard Measure to assess disability.

The pre-specified statistical analysis plan for the primary efficacy endpoint, the change in six minute walk distance at 180 days post infusion involved a primary analysis and a secondary analysis. It's now my pleasure to give you the primary results of the study.

The primary analysis of the primary efficacy endpoints, the primary analysis compared the change from baseline in six minute walk test distance for the four Lomecel-B cohorts to the placebo cohort of day 180, the average baseline six minute walk test was comparable for all groups and the entire population average was 311 meters, which clearly indicates an impaired mobility.

There were statistically significant increases in the highest three doses of 50 million, the 100 million and the 200 million Lomecel-B cohorts and no significant changes in the placebo for the lowest dose of Lomecel-B.

However, after adjusting for multiple comparisons using the Hochberg method four Lomecel-B cohorts did not show a statistically significant placebo-adjusted difference compared to placebo.

These changes were 0.2 in the 25 million, p 0.9902, 27.7 meters in the 15 million p 0.1279, change of 16.8 meters in the 100 million p equals 0.3472 and change compared to placebo in the 200 million of 41.3 meters p 0.0635.

However, the 200 million dose group did get close and unfortunately had a smaller cohort size compared to the rest of the cohorts.

Now, despite not achieving the statistical significance for the peer-wide comparison to placebo at day 180 significant differences from placebo were observed at day 270 with a 50 million and 200 million Lomecel-B cohorts, which was a pre-specified exploratory endpoint. I would now like to show the slides, please Brendan..

Yes..

The secondary analysis of the primary endpoint was to determine whether a dose response relationship exists using the multiple comparisons and modeling approach described by Bretz et. al. We were extremely pleased to see a clear statistically significant dose response curve at day 180.

Among the various dose response curves evaluated, which are statistical modeling techniques, Emax, Linear, Exponential, Quadratic, and Sigmoid Emax all had a p-value of less than 0.05 bonds with the Sigmoid Emax model having the most significant dose-response relationship p equals 0.017.

This was one of the primary objectives of the study, and we believe that this may be one of the very first MSCs studies to show a dose response based on review of previously published studies in the public domain.

The study's key secondary endpoints were day 180 change in the patient reported outcome questionnaire PROMIS, Physical Function, Short Form 20a, SF-20a, total score and day 180 change in serum levels of tumor necrosis factor alpha, an inflammatory cytokine.

The Lomecel-B cohorts did not show a statistically significant difference compared to the placebo cohort in the SF-20a score, and the TNF-α analysis is still pending as of the rest of the biomarkers.

The remainder of the efficacy endpoints, which included assessment of physical function, sexual function, fear and risk of falling, depression, cognition, frailty status, pulmonary function, and clinical outcomes, were considered exploratory and Lomecel-B-treated groups did not show significant differences versus placebo at most of the time points for any of these endpoints.

Based on the results observed at 270 days, we believe that a larger and/or extended trial would have a greater likelihood of achieving statistical significance and that there is strong evidence to support a continued dose dependence response.

Baseline demographics and the trial will balance between the treatment groups and analysis of adverse events, laboratory tests, vital signs, and body weights demonstrated that patients on active Lomecel-B dose groups were generally comparable to the placebo group with respect to safety.

There were no serious adverse events reports that were considered related to Lomecel-B infusion.

The full body of results of the study will be exceptionally valuable to inform the continued advancement of Lomecel-B for the treatment of Aging Frailty in addition to the other disease indications, which we are investigating as we engage in further discussion with the FDA and other international regulatory bodies.

Based on these results, Longeveron is committed and determined to continue pursuing Lomecel-B as a pioneering treatment to ameliorate the detrimental symptoms and address the critical and medical unmet medical need in Aging Frailty.

We look forward to presenting the full results of this trial next month at the upcoming 2021 International Conference of Frailty & Sarcopenia Research on September 29th. I thank you for your attention. And at this point, I would like to turn the call over to Geoff Green, CEO of Longeveron for a general business update.

Geoff?.

Thank you, Dr. Hare. Good morning everyone and thanks again for attending Longeveron's second quarter 2021 business update and earnings call. I'm excited about the Phase 2b results and to share the tremendous progress we have made this quarter and this year. It's been busy and productive quarter.

I'm going to start with an update on our various research programs, provide progress updates, and then anticipated near-term catalysts for 2021. And following this James Clavijo will go through the financial performance for the quarter.

And since we're still a relatively new public company and there may be a first time listeners on the call, I'm going to spend a minute reintroducing the company and our lead therapeutic product to the audience.

So Longeveron is a leading clinical stage biotechnology company that's developing cell therapies for chronic aging related diseases and other life-threatening conditions for which there are no approved treatments.

So aging is the number one risk factor for chronic disease stem cell exhaustion, cellular senescence and chronic inflammation together referred to as inflammaging compromises our ability to repair and regenerate damaged tissues and organs.

Inflammaging is linked to the rise of progressive chronic diseases such as Alzheimer's disease and Aging Frailty. Our focus since day one has been to develop safe and effective allogeneic cell therapy solutions for the treatment and prevention of these diseases.

Our lead therapeutic investigational product called Lomecel-B is a living cell biologic made from the specialized cells isolated from the bone marrow of young healthy adult donors.

These cells called medicinal signaling cells, or MSCs, reside within various tissues in our bodies and are considered to be the body's indogenous or built-in repair mechanism that promotes regeneration of damaged tissues and organs. When we're young, we have an adequate supply of these cells and they function as intended.

Unfortunately, in both humans and animals, there is a clear age related decline in both the number and potency of these cells. And this is believed to be one of the primary reasons for age associated increase in chronic disease. So now I'll provide an update on our Lomecel-B clinical research programs aside from the Aging Frailty program that Dr.

Hare went through and let's begin with the Alzheimer's disease program. So this past April, we announced additional results from our Phase 1 Alzheimer's disease clinical study. Safety data showed that Lomecel-B was safe and well tolerated in this population with no serious adverse events reported.

They were considered related to the investigational product, nor any evidence of Amyloid Related Imaging Abnormalities otherwise known as ARIA, which is a brain swelling issue as assessed by MRI.

While this was a small study intended to demonstrate safety and tolerability, exploratory results showed that the low dose Lomecel-B treated subjects had a slower decline in cognitive function compared to placebo treated subjects over 52 weeks as measured by the Mini Mental State Exam.

The difference compared to placebo reached statistical significance at 13 and 39 weeks post-treatment. The high dose did not showed statistical significance versus placebo. We view these results with cautious optimism due to the fact that it is a Phase 1 trial with a small sample size.

That said we have a manuscript of the results currently under review for peer-reviewed publication and we look forward to initiating the larger Phase 2 study in Alzheimer's disease subjects later this year. Turning now to our Hypoplastic Left Heart Syndrome, or HLHS program.

HLHS is a rare congenital heart defect that affects approximately 1,000 babies per year in the U.S. Babies with HLHS are born with an underdeveloped left ventricle, which impairs the heart's ability to pump blood throughout the body.

The condition is fatal without surgical intervention and even with surgery HLHS is unfortunately associated with a very high mortality and need for heart transplantation.

We completed a Phase 1 study that showed that intramyocardial injection of Lomecel-B during the second stage surgery known as the Glenn procedure was safe and well tolerated, and we achieved our primary safety endpoint of no major cardiac – no major adverse cardiac events reported and no infections within the first 30 days that were considered related to the investigational treatment.

Because of the achievement of completing the Phase 1 study, we are very pleased that the program has now transitioned to Phase 2 with the first baby randomized and treated on June 30th of this year as previously disclosed.

The trial is being funded by a grant from the NIH's National Heart, Lung & Blood Institute in collaboration with Longeveron and is led by principal investigator, Dr. Sanjay Kaushal, Pediatric Cardiothoracic Surgeon at the Lurie Children's Hospital at Chicago.

The trial has a target enrollment of 38 infants and will be enrolling in seven hospitals in major metropolitan centers located throughout the U.S. Now let's touch on our Acute Respiratory Distress Syndrome or ARDS program.

We have an actively enrolling randomized double-blind multi-center 35 subject Phase 1 study, evaluating Lomecel-B infusion in COVID-19 patients with RDS. We anticipate that enrollment in the trial will continue into 2022 with data available either late 2022 or in 2023. The trial is funded in part by a Maryland Stem Cell Research Fund, TEDCO brand.

As a general note, we have historically been successful in our opinion applying for and receiving grant awards to help fund our research with over $15 million awarded to our programs, to date.

With the new data coming out of our various trials and our track record in achieving our state of the aims in our grant programs and successful execution of our clinical trials as part of our funding strategy, we will continue to apply for grants that we believe will further our goal of commercializing Lomecel-B.

And finally, another important highlight from the last quarter is the continued expansion of our executive advisory team. In May we announced the appointment of Judge Ursula Ungaro to our Board of Directors and Dr. Dan Gainesville to our Executive Team of Senior Vice President, Strategic Collaborations and Scientific Affairs.

Both individuals add breadth and depth of expertise and experience to Longeveron and the commitment to our mission is a Testament to both quality of our science and the profound potential of Lomecel-B as a potential treatment for cardiac disease. We are proud and excited to have them on Board.

I'd like now like to turn the call over to James Clavijo, CFO to discuss the financial results for the second quarter of 2021.

James?.

Thank you, Geoff. Good morning, everyone. Most of what I'll be covering this morning has been presented in more detail in our consolidated financial statements and our management's discussion and analysis operations for the three months ended June 30th, 2021, which has been filed – which will be filed today.

Second quarter ended March – revenues for the three months ended June 30, 2021 and 2020 were $0.5 million and $0.9 million respective. The $0.4 million or 44% decrease when compared to the same period in 2020 was primarily due to a decrease in grant revenue year-over-year and grant revenue compared to that recorded in 2020.

Grant revenue for the three months ended June 30, 2021 and 2020 was $0.3 million and $0.9 million respectable. The $0.6 million or 68% decrease when compared to the same period of 2020 was primarily due to a reduction in grant funds available to the completion – due to the completion of the grant funded clinical trials.

Clinical trial revenue, which comes from The Bahamas Registry Trial for the three months ended June 30, 2021 and 2020 was $0.2 million and zero dollars respectable. Clinical trial revenue for the three months ended June 30, 2021 was $0.2 million or 100% higher when compared to the same period in 2020.

During the second quarter of 2020 clinical trial revenue, which is comprised of a Bahamas Registry Trial was negatively impacted by COVID-19 travel restrictions as participants face travel restrictions, as well as concerns for international travel.

Related cost of revenue was $0.3 million and $0.8 million for the three months ended June 30, 2021 and 2020 respectively. The $0.5 million or 63% decrease when compared to the same period in 2020 was primarily due to lower costs of revenues for grants incurred in 2021.

This resulted in a gross profit of $0.2 million for three months into June 30, 2021, and an increase of $0.1 million or 86% when compared with a gross profit of $0.1 million for the same period in 2020. Research and development expenses for the three months ended June 30, 2021 increased to $2 million for $0.7 million for the same period of 2020.

The increase of $1.3 million or 205% was primarily due to an increase in research and development expenses that were not reimbursable by our grants, as well as a $0.8 million increase in our equity-based compensation.

General and administrative expenses for the three months ended June 30, 2021 increased at $3.2 million compared to $0.6 million for the same period in 2020, the increase of 2.6 million or 400 was primarily related to an increase for compensation insurance and professional expenses incurred during the current period, including $1.4 million of equity-based compensation recorded for our RSU stock options for 2021 general administrative expenses consistent, primarily are rent, professional fees, insurance, and paid an accrued compensation.

Net loss increased approximately $5 million for the three months ended June 30, 2021 from a net loss of $1.2 million for the same period in 2020. Our cash and short-term investments as of June 30, 2021 was $21.4 million compared to $0.8 million as of December 31, 2020.

The increase in cash and our short-term investments, period-over-period was a result of our completion in our initial public offering in February of 2021, our cash in the six months into June 30, 2021 was increased by $29.1 million and funds received from our IPO.

As of June 30th as mentioned our cash position which includes short terms investments was $21.4 mil. We believe based on the current operating plan and financial resources that our existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

With that, I will turn the call back to Geoff for closing remarks.

Geoff?.

Thank you, James. So as Dr. Hare explained in detail, we have wealth of data from our now completed Phase 2b trial, and we will love to move to the next step of clinical development of Lomecel-B for treatment of Aging Frailty.

And we'll also be receiving more data shortly related to the biomarkers from that trial as well as the data from the HERA trial expected this – later this quarter. And we'd like to thank the clinical investigators and patients and our research partners who participated in the Phase 2 trial.

Our dedicated employees for their diligence efforts, the NIA of course for their funding and support and our committed shareholders for their ongoing support.

We're excited to be underway on the Phase 2 HLHS trial and look forward to initiating both the Phase 2 Alzheimer’s disease and Japanese Aging Frailty trials later this year, and we'll continue to provide updates as progress is made.

We're well-positioned in terms of capital to advance these programs forward and hit the milestones and catalysts that I've outlined during this update. At this point, I'd like to open the call for questions.

Operator?.

Operator:.

Thank you. So I think we've done the concluding remarks and at this point I'd like to thank everybody for attending the call and I look forward to further updates..

This now completed today's call. Thank you everyone for joining. You may now disconnect..